Notably, JMJD1C knockdown demonstrated the most pronounced inhibitory effect on these pathways, consistent with other studies that identified JMJD1C as a coactivator of leukemogenic transcription programs and a crucial epigenetic regulator for the maintenance of AML [44, 45, 46]. Here, JMJD1C is linked to acute myeloid leukemia.